Acquisition expands Pharmaron’s integrated offerings to clinical development phase​

BEIJING--(BUSINESS WIRE)--

Pharmaron, a fully integrated contract research organization offering R&D services to the life sciences industry, today announced that it has signed a definitive agreement under which Pharmaron will acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (“SNBL CPC”) in Baltimore, Maryland, USA. This clinical center is a leading provider of moderate and highly complex Phase I/II clinical development services for the life sciences sector. Current shareholder Shin Nippon Biomedical Laboratories, Ltd. (SNBL) (TSE:2395) will retain a minority stake in the business following the transaction.

This Smart News Release features multimedia. View the full release via BusinessWire here: http://www.businesswire.com/news/home/20170228006069/en/

Click here to read the rest of the story via YAHOO! Finance

http://www.businesswire.com/news/home/20170228006069/en/ ' data-reactid="16">